Emerald Bioscience (EMBI) Starts Presentation at 9th Annual LD Micro Invitational
Emerald Bioscience (OTC: EMBI) is focused on advancing the medical benefits of cannabinoid-based therapies through its novel, proprietary, multi-cannabinoid drug platform for the treatment of significant unmet medical needs. This bioengineered platform, pioneered by the University of Mississippi, is considered an early mover in cannabinoid drug development. Modifying the molecules of the cannabis plant and creating synthetic cannabinoid derivatives, results in an optimized cannabinoid technology that enhances bioavailability and delivers more predictable pharmacokinetics. For more information, visit the company's website at www.emeraldbio.life. About NetworkNewsWire NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication…







